{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xie H"],"funding":["Clinical Comprehensive Drugs Evaluation in Jiangsu Province","Special Fund for Clinical Research of Nanjing Drum Tower Hospital","National Natural Science Foundation of China"],"pagination":["269-283"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10920562"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(2)"],"pubmed_abstract":["Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for osteoarthritis (OA), but prolonged use has adverse effects and varying efficacy. Among NSAIDs, imrecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces side effects yet remains ineffective for half of the patient population. This study aims to identify biomarkers for early evaluation of imrecoxib efficacy in OA for personalized therapy optimization.Methods
From September 2021 to January 2022, imrecoxib was administered to patients with OA at Nanjing Drum Tower Hospital. Plasma samples from these patients underwent proteomic analysis through the four-dimensional data-independent acquisition (4D-DIA) method, followed by bioinformatics analysis. Potential differentially expressed"],"journal":["Rheumatology and therapy"],"pubmed_title":["Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis."],"pmcid":["PMC10920562"],"funding_grant_id":["2021-LCYJ-PY-07","72104105"],"pubmed_authors":["Zhu Z","Ge W","Xie H","Zhang Y","Wei J","Ainiwaer G"],"additional_accession":[]},"is_claimable":false,"name":"Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis.","description":"Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for osteoarthritis (OA), but prolonged use has adverse effects and varying efficacy. Among NSAIDs, imrecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces side effects yet remains ineffective for half of the patient population. This study aims to identify biomarkers for early evaluation of imrecoxib efficacy in OA for personalized therapy optimization.Methods
From September 2021 to January 2022, imrecoxib was administered to patients with OA at Nanjing Drum Tower Hospital. Plasma samples from these patients underwent proteomic analysis through the four-dimensional data-independent acquisition (4D-DIA) method, followed by bioinformatics analysis. Potential differentially expressed","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-07-14T20:53:54.406Z","creation":"2026-06-24T03:04:12.718Z"},"accession":"S-EPMC10920562","cross_references":{"pubmed":["38236456"],"doi":["10.1007/s40744-023-00636-z"]}}